Oppose Illinois House Bill 4900
Everyone supports containing skyrocketing prescription drug prices but HB 4900, sponsored by Rep. Will Guzzardi (D-Chicago), would actually just make the problem worse for Illinois patients. Price gouging– targeted by this bill – is unacceptable. But we must employ sound public policy to both weed out bad apples and enhance a market where they cannot […]
Rate-Setting Bills
AAM’s core mission is to improve patients’ lives by advancing timely access to affordable, FDA-approved generic and biosimilar medicines. AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines. Our members provide more than 36,000 jobs at nearly 150 facilities, and manufacture more than 61 billion doses of […]
Oppose New Hampshire House Bill 1780
Everyone supports containing skyrocketing prescription drug prices. Unfortunately, H.B. 1780 sponsored Rep. Rebecca McBeath (D-District 26), makes the problem worse for New Hampshire patients and our economy. While well-intentioned, Rep. McBeath’s bill doesn’t address the real cause of high drug prices, and would penalize FDA-approved generics – the medicines that have been reliably affordable for […]
Oppose Virginia Senate Bill 223
Everyone supports containing skyrocketing prescription drug prices but S.B. 223, sponsored by Sen. John Edwards (D), would actually just make the problem worse for Virginia patients and our economy. While well-intentioned, Sen. John Edward’s bill doesn’t address the real cause of high drug prices, and would penalize FDA-approved generics — the medicines that have been […]
Protect Generic Rx Access for Minnesota Patients
Don’t Harm Patient Access to FDA-approved Generic Medicines by Chilling Generic Drug Competition Everyone supports containing skyrocketing prescription drug prices, but the A-74 provision that was added to the omnibus bill will actually just make the problem worse for Minnesota patients and our economy, and has already been found unconstitutional in another state. Generic medicines saved […]
Stories and Data: How AAM Equips Advocates in the States
Drug prices matter to patients and their families. If a medicine isn’t affordable, it isn’t accessible. David Mitchell, founder of Patients for Affordable Drugs, has called drug pricing “a genuinely bipartisan issue.” The Association for Accessible Medicines (AAM) and our allies see federal and state solutions. In recent years, the national dialogue about drug pricing […]
A Generic Summer Savings Tour: How Did Your State Do?
The 11th edition of the Association for Accessible Medicines’ annual Access and Savings Report (see summary) reveals how much money American patients and taxpayers saved in 2018 through competition from generic drugs and biosimilar alternatives to brand-name biologic medicines. The report provides data by state, based on findings by IQVIA. We’re releasing a detailed publication […]
AAM Statement on House Bills 965, 1499 and 938
WASHINGTON, DC (May 21, 2019) — AAM commends the House of Representatives for passing H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act). This important, bipartisan legislation will help lower prescription drug prices for American patients by closing regulatory loopholes that have been abused by some brand-drug manufacturers […]
Andrew O’Connor Joins AAM as Manager, State Government Affairs
WASHINGTON DC (December 10, 2018) – Today Andrew S. O’Connor is joining the Association for Accessible Medicines (AAM) Government Affairs team as Manager, State Government Affairs. He will manage the tracking of state legislation and regulations and provide the team with administrative and operational support. Andrew previously served as Legislative Associate, Healthcare and Insurance, at […]
Take Action on SB 17 to Protect Patient Access and Savings for Californians
Generic drugs have been lowering health care costs in California for decades, saving California $21.7 billion in 2016 alone. In fact, generics make up 89 percent of all prescriptions administered, yet account for only 26 percent of total drug costs. Legislative efforts in Sacramento to reduce the financial burden of health care are laudable, but […]
Veto Maryland House Bill 631, Which Would Harm Patients by Chilling Generic Drug Competition
Everyone supports proposals to control rising prescription drug prices, but H.B. 631 would just make the problem worse for Maryland patients and our economy. Chester “Chip” Davis, Jr. calls on Governor Hogan in a commentary article for Maryland Matters to veto H.B. 631, legislation that would decrease generic drug competition in Maryland. “In order to preserve the savings that generic […]
Oppose Colorado House Bill 1179
Everyone supports containing skyrocketing prescription drug prices, but H.B. 1179 would actually just make the problem worse for Colorado patients and our economy. The same bill became law in Maryland but was later found unconstitutional. H.B. 1179 ignores the realities of the prescription drug marketplace. Inexplicably, the bill applies only to generic drugs — products that save the […]
